BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth L. Londoner purchased 15,000 shares of the company’s stock in a transaction on Monday, May 20th. The shares were purchased at an average cost of $7.78 per share, with a total value of $116,700.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
BSGM traded up $0.44 during mid-day trading on Friday, reaching $7.91. 178,286 shares of the company traded hands, compared to its average volume of 129,069. The company has a current ratio of 10.99, a quick ratio of 10.99 and a debt-to-equity ratio of 0.02. BioSig Technologies Inc has a 52-week low of $3.50 and a 52-week high of $9.97.
BioSig Technologies (NASDAQ:BSGM) last issued its quarterly earnings results on Monday, April 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). As a group, analysts forecast that BioSig Technologies Inc will post -1.17 earnings per share for the current fiscal year.
A number of research firms have weighed in on BSGM. Laidlaw set a $11.00 target price on BioSig Technologies and gave the stock a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research downgraded BioSig Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, May 22nd.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Morgan Stanley increased its stake in shares of BioSig Technologies by 212.1% in the 1st quarter. Morgan Stanley now owns 11,547 shares of the company’s stock worth $71,000 after purchasing an additional 7,847 shares in the last quarter. Jefferies Group LLC purchased a new stake in shares of BioSig Technologies in the 1st quarter worth $515,000. Northern Trust Corp purchased a new stake in shares of BioSig Technologies in the 1st quarter worth $80,000. BlackRock Inc. purchased a new stake in shares of BioSig Technologies in the 1st quarter worth $365,000. Finally, Cambridge Investment Research Advisors Inc. increased its stake in shares of BioSig Technologies by 49.8% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 90,000 shares of the company’s stock worth $553,000 after purchasing an additional 29,922 shares in the last quarter. 4.87% of the stock is owned by institutional investors and hedge funds.
WARNING: “Kenneth L. Londoner Acquires 15,000 Shares of BioSig Technologies Inc (NASDAQ:BSGM) Stock” was originally published by Sundance Herald and is the property of of Sundance Herald. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://sundanceherald.com/2019/06/14/biosig-technologies-inc-bsgm-ceo-acquires-116700-00-in-stock.html.
BioSig Technologies Company Profile
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Featured Article: Roth IRA
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.